UBS Oncology Impact Fund L.P., 10% Owner at Cullinan Oncology, Inc. (CGEM), sold 45,780 shares at $29.47 ($1.3M) on 2021-09-01, disclosed to the SEC on 2021-09-02.
Scheduled sale ($1.3M) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.43 | 1,285 | $38K | 2.8% |
| 2 | $30.14 | 1,553 | $47K | 3.5% |
| 3 | $29.47 | 5,714 | $168K | 12.5% |
| 4 | $29.47 | 5,714 | $168K | 12.5% |
| 5 | $29.46 | 15,757 | $464K | 34.4% |
| 6 | $29.46 | 15,757 |
| $464K |
| 34.4% |
| Total | $29.48 avg | 45,780 | $1.3M | 100% |
| Filing → |
| HOWL | SELL | 2025-10-29 | $685K | — | Filing → |
| ITOS | SELL | 2021-09-27 | $3.2M | — | Filing → |
| HARP | SELL | 2021-05-24 | $541K | — | Filing → |